LK-4 (ATCC® CRL-2345)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Applications
The hybridoma cell line LK-4 secretes a mouse monoclonal antibody (IgG1k) that recognizes human platelet glycoprotein GPIIIa.
The antibody can differentiate platelet PLA1/PLA1, PLA1/PLA2 and PLA2/PLA2 genotypes on soluble platelet extracts; it can recognize but not differentiate intact platelets.
The antibody is useful in immunoblot and ELISA assays.
The line was produced by fusing P3U1 mouse myeloma cells with spleen cells from a BALB/c female mouse differentially immunized with human PLA2 platelets and cyclophosphamide, followed by PLA1 platelets.
Derivation
The line was produced by fusing P3U1 mouse myeloma cells with spleen cells from a BALB/c female mouse differentially immunized with human PLA2 platelets and cyclophosphamide, followed by PLA1 platelets.
Clinical Data
The line was produced by fusing P3U1 mouse myeloma cells with spleen cells from a BALB/c female mouse differentially immunized with human PLA2 platelets and cyclophosphamide, followed by PLA1 platelets.
Genes Expressed
immunoglobulin; monoclonal antibody; against human platelet glycoprotein GPIIIa.
Cellular Products
immunoglobulin; monoclonal antibody; against human platelet glycoprotein GPIIIa.
Comments
The hybridoma cell line LK-4 secretes a mouse monoclonal antibody (IgG1k) that recognizes human platelet glycoprotein GPIIIa.
The antibody can differentiate platelet PLA1/PLA1, PLA1/PLA2 and PLA2/PLA2 genotypes on soluble platelet extracts; it can recognize but not differentiate intact platelets.
The antibody inhibits binding of human anti- PLA1 antibody to human platelets.
The antibody is useful in immunoblot and ELISA assays.
The line was produced by fusing P3U1 mouse myeloma cells with spleen cells from a BALB/c female mouse differentially immunized with human PLA2 platelets and cyclophosphamide, followed by PLA1 platelets.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain
Name of Depositor S Karpatkin
References

Liu LX, et al. A monoclonal antibody (LK-4) which differentiates PLA1 from PLA2 platelet extracts but not intact platelets. Thromb. Res. 66: 309-320, 1992. PubMed: 1384161

Liu LX, et al. Development of a monoclonal antibody capable of differentiating platelet PLA1/PLA1, PLA1/PLA2 and PLA2/PLA2 genotypes. Br. J. Haematol. 81: 113-117, 1992. PubMed: 1520609

Liu LX, et al. Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIIa. Br. J. Haematol. 91: 976-982, 1995. PubMed: 8547151

Valetin N, et al. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood 85: 3028-3033, 1995. PubMed: 7756638

Liu LX, et al. Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Blood 88: 3601-3607, 1996. PubMed: 8896429

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Liu LX, et al. A monoclonal antibody (LK-4) which differentiates PLA1 from PLA2 platelet extracts but not intact platelets. Thromb. Res. 66: 309-320, 1992. PubMed: 1384161

Liu LX, et al. Development of a monoclonal antibody capable of differentiating platelet PLA1/PLA1, PLA1/PLA2 and PLA2/PLA2 genotypes. Br. J. Haematol. 81: 113-117, 1992. PubMed: 1520609

Liu LX, et al. Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIIa. Br. J. Haematol. 91: 976-982, 1995. PubMed: 8547151

Valetin N, et al. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood 85: 3028-3033, 1995. PubMed: 7756638

Liu LX, et al. Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Blood 88: 3601-3607, 1996. PubMed: 8896429